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SUMMARY
The anaesthetic effects of intravenous administration oftiletamine (2.5 mg/kg) - zolazepam (2.5 mg/kg) mixture
(TZ), and tiletamine (0.5 mglkg) - zolazepam (0.5 mg/kg) - ketamine (1.6 mg/kg) - xylazine (0.4 mg/kg) mixture
(TKX) were evaluated in ten dogs. Atropine sulphate at a dose rate ofO.05 mg/kg was administered concurrently with
the anaesthetic mixtures. Both mixtures produced rapid, smooth induction, and allowed intubation. The TKX mixture
produced longer skin clamp analgesia and immobilisation, better jaw relaxation, with shorter and smoother recovery
compared to TZ injection. The TKX mixture induced significant but transient pallor of mucous membranes « 2 min).
The TZ mixture resulted in increased heart rate and a higher respiratory rate compared to TKX mixture. Haemoglobin
saturation was < 90% in some dogs following either mixture. The TKX mixture can be considered as an alternative
injectable mixture to TZ for short and minimally invasive procedures in patients that have no cardiopulmonary
dysfunction.
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INTRODUCTION
Injectable anaesthetics are commonly employed to
provide sedation, analgesia and immobilisation to
facilitate examination and minor surgical procedures such
as radiographic procedure, skin punch biopsy, superficial
wound debridement and suturing, external reduction and
stabilisation of fractures or luxation in small animals. The
combination oftiletamine and zolazepam (TZ) at a ratio
of 1: 1 is available commercially, and is marketed as
Zoletil® (Virbac Pty Ltd., NSW, Australia) or Telazol®
(Fort Dodge Lab., lA, USA). The use of this combination,
either alone, or with other anaesthetics or adjuncts has
been described in cats, dogs, horses, ruminants, and exotic
and wildlife species (Lin, 1996).
At the Universiti Putra Malaysia Veterinary Hospital,
intravenous (IV) administration of the commercial TZ
combination has routinely been used in both dogs and
cats for minor procedures not lasting longer than 45-60
minutes. The typical practice involved an initial IV dose
of5 mg/kg and a top up of 113 to 112 of the initial IV dose
when needed. This practice provided reliable
immobilisation and appeared to be safe. However,
recovery in dogs appeared to be rough. Muscle rigidity
and seizure-like activity described by Short (1989) has
also been observed in some dogs (Chen, unpublished
observation). The relatively higher cost of the commercial
TZ prompted a trial where ketamine and xylazine were
added into the combination.
The use of the tiletamine, zolazepam, ketamine and
xylazine mixture (TKX) has been reported in pigs (Ko et
al., 1993a; 1994), sheep (Lin et al., 1994), cats (Ko et al.,
1993b; Dullard, 1994; Williams et al., 2002), emus (Boyd
and Day, 1995) and ferrets (Dullard, 1994). All have
commented that it provides satisfactory restraint.
In Malaysia, some small animal practitioners have
tried the TKX mixture in dogs and found it to be useful
and reliable, with minimal morbidity (Yeoh, personal
communication). The mixture is prepared by adding 4
ml of 100 mg/ml ofketamine and 1 ml of 100 mg/ml of
xylazine into a vial of 250 mg freeze-dried TZ. The
mixture is administered at an IV dose rate ofO.02 ml/kg
with a maximum total dose of 0.5 ml per dog. A lower
dose rate ofO.Ol - 0.015 ml/kg is used on older dogs. To
our knowledge, there are no objective studies
documenting the duration of anaesthetic effects of the
TKX combination in dogs. Therefore, this study was
undertaken to evaluate and compare the anaesthetic effects
of a pre-set dose ofTKX mixture to the commercial TZ,
administered intravenously in dogs.
MATERIALS AND METHODS
Animals
Ten adult local mixed-breed pound dogs, weighing
10.7 ± 1.6 (mean ± SD) kg were used. They were judged
to be normal based on physical examination and vital
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signs. The dogs were adapted to individual kennels, fed
on dry dog pellet and water ad libitum, daily leash-walk
and handling for a minimum of three days before the study. -
Food was withheld 12 hours prior to each experiment.
Anaesthetic protocols
The two pre-set doses of anaesthetic mixtures were:
(i) TKX mixture:
0.5 mg/kg tiletamine, 0.5 mg/kg zolazepam, 1.6 mg/
kg ketamine and 0.4 mg/kg xylazine.
The TKX mixture was prepared by adding 4.0 ml of
100 mg/ml ketamine (Ketavet 1OO®DELVET Pty Ltd,
NSW, Australia) and 1.0 ml of 100 mg/ml xylazine
(Xylazil 1OO®TROY Lab Pty Ltd, NSW, Australia)
into a vial of freeze-dried 250 mg tiletamine-
zolazepam (Zoletil® 50, Virbac Pty Ltd., NSW,
Australia). The TKX mixture was administered at
0.02 mllkg, similar to the dose rate used by the small
animal practitioners.
(ii) TZ mixture:
2.5 mg/kg tiletamine and 2.5 mg/kg zolazepam.
The provided 5 ml diluent was used to reconstitute a
vial of 250 mg freeze-dried tiletamine-zolazepam
(Zoletil® 50, Virbac Pty Ltd., NSW, Australia). The
TZ mixture was administered at 0.1 mllkg.
Atropine sulphate (Atrosite, TROY Lab Pty Ltd.,
NSW, Australia) at a dosage of 0.05 mg/kg was mixed
with the anaesthetics into the same syringe immediately
prior to administration.
Experimental protocol and data collection
The dogs were assigned to the two anaesthetic
mixtures in a cross-over design, with three days interval
between each experiment. One observer evaluated and
collected data from all the dogs. The observer was not
blinded to the anaesthetic mixtures assigned.
Baseline (time at 0minute) heart and respiratory rate
were taken just before the IV induction. Once induced,
and sufficient jaw relaxation was achieved, the dogs were
intubated and placed on left lateral recumbency. Buccal
mucous membrane colour, respiratory rate, heart rate,
haemoglobin saturation, medial palpebral and pedal
reflexes, and response to noxious stimulus were
determined at two minutes following induction and
subsequently at three minute intervals thereafter, until the
dogs regained righting reflex. Respiratory rate was
determined from observation of chest excursion and heart
rate was based on chest auscultation using a stethoscope,
both counted within 20 seconds. The haemoglobin
saturation (Sp02) was determined using pulse oximetry
via the tongue probe (Vet Ox 44022® Sensor Devices Inc.,
Waukesha, USA). Medial palpebral reflex was elicited
by gently touching the medial canthus. Pedal reflex was
evaluated by finger-pinching the third interdigital web of
the right hind limb. Superficial pain was stimulated using
an Allis forcep to clamp (three rachet) a fold of skin,
incorporating the subcutaneous tissue at the last rib. A
Rochester-Pean was used to clamp firmly (one rachet) a
tail segment incorporating a coccygeal vertebra to
stimulate deep pain. Different skin folds and tail segments
of adjacent sites were used subsequently to prevent tissue
injury.
The time from injection to recumbency, first
respiration, presence of response to skin clamp and tail
clamp, return of medial palpebral and pedal reflex,
intolerance to intubation, righting reflex, sternal recovery,
standing and walking were noted. Increased respiratory
rate, muscle fasciculations, vocalization, body movements
or a combination of these were defined as response to
noxious stimuli. The dogs were extubated when they
showed swallowing reflex at least four times continuously.
Return of righting reflex was taken as the time when the
dog first lifted its head. Sternal recovery was taken as the
time when the dog could maintain its sternal position
without assistance. Standing was taken to be the time
when the dog attempted to rise on all four legs. The quality
of recovery was given a score of 1 to 5 as described below
with a higher score indicating better recovery: '
Score 1 - Violent excitement during recovery
Score 2 - Ataxic before standing, several attempts to rise,
very ataxic once standing
Score 3 - Quiet recovery, gained standing position after
several attempts, ataxic when standing or
walking
Score 4 - Good quiet recovery, gained standing position
at first attempt, mildly ataxic when standing or
walking
Score 5 - Good quiet recovery, gained standing position
at first attempt, not ataxic when standing or
walking
The data were analysed for anaesthetic effect using
paired t-test, Wilcoxon sign rank test and ANOVA for
repeated measures as appropriate. Within the anaesthetic
mixtures, Dunnett's test was applied to compare for
differences from baseline. A p-value of < 0.05 was
considered significant.
RESULTS
The duration of anaesthetic effects for both
combinations are summarised inTable 1. All dogs became
recumbent rapidly following IV administration of either
mixture, with no difference between them. The duration
of apnoea (time from injection to first respiration) was
significantly shorter in TKX treated dogs. All dogs
induced with both the anaesthetic mixtures could be
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Table 1: Duration of anesthetic effects following intravenous administration ofTZ (tiletamine-zolazepam)
and TKX (tiletamine-zolazepam-ketamine-xylazine).
Parameters TZ TKX p-value
13.3 ± 0.96 14.8 ± 0.63 0.234
48.4 ± 3.15 35.00 ± 2.88 0.000*
18.8 ± 3.06 15.90 ± 1.43 0.401
8.00± 1.26 17.30 ± 1.92 0.010*
5.00± 0.00 5.90 ± 0.46 0.081
8.90± 2.10 18.2 ±2.06 0.015*
30.8 ± 4.03 21.00 ± 2.06 0.085
36.20± 3.73 23.10 ± 2.48 0.035*
55.6 ± 6.78 28.90 ± 2.32 0.008*
TI to recumbency (second)
TI to first respiration (second)
Duration of intubation (minute)
TI to skin clamp positive response (minute)
TI to tail clamp positive response (minute)
TI to presence of pedal reflex (minute)
TI to righting reflex (minute)
TI to sternal recovery (minute)
TI to standing or walking (minute)
intubated without difficulty, although four dogs induced
with TZ still maintained some degree of jaw tone. There
was no difference between TZ and TKX for the duration
of intubation.
The duration of skin clamp analgesia (time from
injection to the presence of positive response to skin
clamp) and absence of pedal reflex were significantly
longer with TKX. Tail clamp analgesia also tended to last
longer with TKX administration but was not significant.
However, time from injection to righting reflex tended to
be shorter with TKX. Time from injection to sternal
recovery, and standing or walking was significantly
shorter with TKX administration.
All dogs induced with TKX showed pallor of the
mucous membrane immediately after induction, and
returned to normal (pink) at 2 minutes. Mucous
membranes remained pink following TZ administration
in all dogs. All dogs had strong palpebral reflexes at two
minutes following TZ administration, while 50% of the
dogs had mild reflexes after TKX administration.
There was no significant change in the heart rate with
TKX, but heart rate was elevated after injection of TZ
(Figure 1). Respiratory rate decreased and remained low
after TKX injection, while TZ-treated dogs had higher
respiratory rate. Two of the dogs showed irregular and
shallow breathing following TZ administration.
Haemoglobin saturation was low immediately after
induction and gradually increased over time in both
groups. Following TZ administration, five dogs had Sp02
less than 90%. With TKX administration, seven dogs did
not register any Sp02 reading at two minutes, and only 6
dogs registered readings thereafter.
The TKX-treated dogs showed significantly
smoother recovery (median score of 4) compared to the
TZ (median score of 2.5) treatment. Ataxia was present
during all stages of recovery following TZ, and dogs
tended to hit their head on the ground during sternal
recovery ifleft unassisted.
Heart Rate
250 •I200
!150
" 100::c
0 2 5 8 11 14 17 20 23
Time (min)
Respiratory Rate
50
? 40!30 I"..:"""~~I!2010 •~ 0
0 2 5 8 11 14 17 20
Time (min)
Haemoglobin Saturation
~ 198~0955~01I_I_.~__~I~__~_I_".~l~~l~!~·~
2 5 8 11 14 17
Time (min)
Data are expressed as mean ± SEM
...Significantly different (p < 0.05) from baseline (0 min)
Fig. 1. Effects on heart rate, respiratory rate and
haemoglobin saturation following intravenous
administration of TZ (tiletamine-zolazepam) and TKX
(tiletamine-zolazepam-ketamine-xylazine)
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DISCUSSION
This study demonstrated that both the TZ and TKX
anaesthetic mixtures resulted in rapid, smooth induction,
and enabled intubation. This study also showed that the
addition ofketamine (1.6 mglkg) and xylazine (0.4 mg/
kg) to a lesser dose of the TZ mixture resulted in longer
duration of skin clamp analgesia and absence of pedal
reflex, yet offered shorter recovery time and better
recovery score. The longer duration of skin clamp
analgesia and absence of pedal reflex in TKX-treated
animals were likely attributed to xylazine. Xylazine is
known to provide analgesia via stimulation of the central
az-receptors (Hsu, 1981). It is also known to cause good
muscle relaxation (Hsu, 1981); this was manifested as
better jaw relaxation during intubation in this study. In
dogs given xylazine at a dose rate of 2.2 mg/kg
intramuscularly, the mean arousal time and mean walk
time were 15.5 and 24.8 minutes respectively, and these
were shortened significantly following administration of
yohimbine (Hatch et al., 1985). Both yohimbine and
atipamezole (az-antagonists) have been used to reverse
the residual effect of xylazine to hasten recovery following
IV administration of TKX (Yeoh, personal
communication). When reversal of an u2-agonist is
needed, atipamezole, a more specific uz-antagonist would
be preferred, as yohimbine can occasionally produce
hypotension (U2 blockade) and tachycardia (Muir, 2002).
The undesirable effects of yohimbine may be prevented
by slow IV administration to achieve the desired arousal,
or by intramuscular injection (Muir, 2002).
The smoother recovery following TKX
administration was likely a reflection of the residual
sedative effect ofxylazine and relatively smaller amount
of tiletamine in the mixture. The characteristic rough
recovery of the dogs given TZ alone may be explained
by the longer plasma half-life of the dissociative drug
tiletamine (1.2 hour), compared to zolazepam (1 hour)
(Baukema and Glazko, 1975).
Intense vasoconstriction and increased vascular
resistance following stimulation of the az-receptors in
the vascular smooth muscles by xylazine is most
prominent following intravenous administration (Klide
et al. 1975). This explains the pale mucous membranes
and failure of the pulse oximeter to detect the vascular
pulsation signal immediately after TKX administration
in this study.
The significant increase in the heart rate following
TZ was likely due to the combined sympathetic-
stimulating effect of tiletamine and the vagolytic effect
of atropine. Even without the addition of atropine, IV
administration of TZ alone has been shown to increase
the heart rate (Hellyer et al., 1989). The absence of
elevation in the heart rate following TKX administration
was likely due to the sympathomimetic effect of the
combination of atropine, ketamine and tiletamine being
antagonized by the xylazine-induced reflex-bradycardia
(Tranquilli, 2002). Although blood pressure was not
measured in this study, xylazine is well known to cause
immediate hypertension due to the intensed
vasoconstriction, leading to the baroreceptor-mediated
reflex-bradycardia (Tranquilli, 2002). It is likely that all
the dogs were hypertensive immediately following TKX.
However, the vagolytic effect of atropine prevented the
reflex-bradycardia, resulting in an unchanged heart rate.
In this study, atropine was used with the rationale to
prevent potential hypersalivation following TZ
administration, and bradycardia following TKX
administration. Besides atropine, glycopyrrolate (another
anticholinergic agent) can be used for similar purpose.
Whether an anticholinergic should be added to an az-_
agonist to prevent bradycardia has been debated. A recent
study (Sinclair et aI., 2003) showed that concurrent use
of glycopyrrolate with romifidine (an u2-agonist)
worsened cardiac performance, increased wall stress and
myocardiac workload. Therefore, routine use of an
anticholinergic together with an u2-agonist is not
recommended, especially in patients with
cardiopulmonary dysfunction. In our study, all dogs
showed tachycardia following concurrent administration
of atropine and TZ. This raises concerns on the increased
myocardiac workload and oxygen consumption. In
retrospect, this study should probably not have included
atropine in the anaesthetic protocol. The degree to which
potential hypersalivation or bradycardia could have been
detrimental without an anticholinergic in the anaesthetic
protocol remains to be determined.
Overall, the average respiratory rate was lower
following TKX administration, but the period of apnoea
was slightly longer immediately after TZ administration.
The longer period of apnoea probably explained the lower
mean Sp02 at two minutes following TZ. However, the
higher mean Sp02 at two minutes following TKX was
based on only 3 readings since the pulse oximeter failed
to register any reading in the other 7 dogs. This higher
mean value may be biased and not adequate for
comparison with TZ to evaluate the pulmonary function.
It is also important to remember that the Sp02 reading
can be influenced by ambient light and local vascular
pulsation signal, which is in turn influenced by systemic
blood pressure, volume status, vasoconstriction and
hypothermia (Grubb, 2002). Ideally, measurement of the
arterial carbon dioxide and oxygen tension would better
evaluate adequacy of the ventilatory function; however,
we were limited by cost and availability of equipment.
It is recommended that the haemoglobin saturation
should be maintained at 90% or higher to prevent
hypoxemia (Grubb, 2002). There is no definite
recommendation on a maximum duration of hypoxemia
that is 'safe' without causing detrimental effect. In this
study, approximately 50% of the readings in the TZ-
treated group, and 20% in the TKX-treated group
registered readings that were lower than 90%. Therefore,
it is advisable to standby supplemental oxygen in the event
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that patients continue to desaturate when using either the
TZ or TKX mixtures.
Both mixtures produced very short duration of tail
clamp analgesia, indicating that these regimens are not
suitable for invasive and painful procedures that last
longer than 5 minutes. Itmay be possible to deepen and
prolong the effects of both anaesthetic mixtures with
additional top-ups. However, the total top-ups should be
limited as this could result in cumulative effect and
prolonged recovery. Furthermore, prolonged sub-optimal
oxygenation in room air without supplemental oxygen
may compromise normal tissue function and lead to
potential tissue damage. Further study on the clinically
relevant effects of additional top-up with these mixtures
would be helpful to guide practitioners.
In this study, the cost ofTKX was one-third that of
TZ. It is an attractive alternative to TZ, as it produces
longer duration of superficial analgesia and
immobilization, better muscle relaxation, with shorter and
smoother recovery. However, as with any anaesthetic
protocols that contain an lXz-agonist, its use should be
restricted to patients without suspected or potential
cardiopulmonary dysfunction (Tranquilli, 2002). Patients
should be exercise tolerant at a minimum and should have
no overt signs of cardiopulmonary disease.
In conclusion, TKX can be considered as an
alternative injectable anaesthetic mixture to TZ. It can be
used either for induction of anaesthesia prior to inhalant
maintenance, or for short and minimally invasive
procedures in patients without cardiopulmonary
dysfunction.
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